What is Evommune 's change in other liabilities?

Evommune (EVMN) reported change in other liabilities of -$11.15K in Q1 2026.

How has Evommune 's change in other liabilities changed year-over-year?

Evommune 's change in other liabilities decreased by 57.8% year-over-year, from -$7.07K to -$11.15K.

What does change in other liabilities mean?

Change in miscellaneous liabilities affecting operating cash flow.

Evommune EVMN Change in Other Liabilities

Change in Other Liabilities at other companies

PfizerPFE

-$916.75M-17.7%

Perrigo CompanyPRGO

$2.7M+640%

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherCurrentLiabilities.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's change in other liabilities?: Evommune (EVMN) reported change in other liabilities of -$11.15K in Q1 2026.
How has Evommune 's change in other liabilities changed year-over-year?: Evommune 's change in other liabilities decreased by 57.8% year-over-year, from -$7.07K to -$11.15K.
What does change in other liabilities mean?: Change in miscellaneous liabilities affecting operating cash flow.